COMMUNIQUÉS West-GlobeNewswire

AltruBio Presents Phase 2a Data of ALTB-268 in Advanced Therapy-Refractory Ulcerative Colitis at UEG Week 2026
20/10/2026
Dose-related clinical activity: Week 12 clinical remission of 23.1% (3/13) in higher-dose Cohort 2 vs. 11.4% (4/35) in lower-dose Cohort 1 38.9% (7/18) of participants with a Day 29 trough concentration at or above the [...]
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
20/10/2026
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS [...]
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
20/10/2026
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS [...]
Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million, Expanding its Rare Disease Pipeline and Gaining a European Base
20/10/2026
, Oct. 20, 2026 (GLOBE NEWSWIRE) -- CAMBRIDGE, UK & UTRECHT, THE NETHERLANDS – October 20, 2026 – Ambrose Healthcare, a rare disease specialist, has acquired 100% of the shares of AM-Pharma. Under the terms of the [...]
Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026
20/10/2026
Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates Allschwil, Switzerland, October 20, [...]
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
20/10/2026
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory [...]
Remote Heart Monitoring at KFSH Reduces Heart Failure Admissions by 46%
20/10/2026
RIYADH, Saudi Arabia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced hospital admissions for decompensated heart failure by 46.4% among patients fitted with an [...]
KFSH Cuts Emergency Department Boarding Time by 75% Through AI-Enabled Patient Flow System
20/10/2026
RIYADH, Saudi Arabia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced median Emergency Department boarding time at its Riyadh hospital by 75%, from more than 13 [...]
XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire
20/10/2026
L’étude sponsorisée par des chercheurs et financée par l’Institut National du Cancer (INCa) atteint le critère de jugement principal d’efficacité préspécifié, avec une survie globale à 12 mois de 61,3 %. L’analyse [...]
Leo International Precision Health AG: Mr Leo Wang, Disposal
19/10/2026
Leo International Precision Health AG: Mr Leo Wang, Disposal Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 19. Oct 2026 [...]
Conavi Medical Announces New Grants of Stock Options
19/10/2026
TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing and marketing [...]
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
19/10/2026
Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit Opportunities LITTLETON, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- [...]
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
19/10/2026
Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage [...]
Clover Health Earns Top Honors in U.S. News & World Report's 2027 Medicare Advantage Ratings Across Three States
19/10/2026
Clover Health plans are named Best Medicare Advantage Plans in New Jersey, Georgia, and South Carolina, scoring highest in all three states for Best for Care Continuity. WILMINGTON, Del., Oct. 19, 2026 (GLOBE NEWSWIRE [...]
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
19/10/2026
SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026
19/10/2026
SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it [...]
Pliant Therapeutics Announces Upcoming Presentation at European Society for Medical Oncology Congress 2026
19/10/2026
Features FORTIFY, the ongoing Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc [...]
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
19/10/2026
The addition of Ms. Peterson and Mr. Coats brings additional commercial and product launch experience to Mineralys ahead of the December 22 PDUFA target action date for lorundrostat RADNOR, Pa., Oct. 19, 2026 (GLOBE [...]
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials
19/10/2026
Expands Fortrea’s early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a more integrated platform for clients Highlights Fortrea completes [...]

Pages